FDA has cleared an investigational new drug (IND) application to study switchable chimeric antigen receptor T cell (sCAR-T) therapy (CLBR001 + SWI019) in patients with autoimmune conditions. Patient ...

The US Food and Drug Administration (FDA) has granted clearance to CureVac's investigational new drug application (IND) for ...

Recruitment for the trial is set to commence shortly, aiming to assess the therapy in treating various conditions.

ST-001, an intravenous nanoformulation of fenretinide, will be evaluated in a phase 1a/1b small cell lung cancer trial.

BrainStorm has attempted to gain market approval for NurOwn without success but remains committed to developing the cell therapy.

The National Cancer Institute’s Investigational New Drug program facilitates collaboration, not collusion, with industry for ...

The FDA granted a positive review for an acute myeloid leukemia drug trial, with initial dosing expected in 2025.

A second phase 1 trial plans to evaluate CER-1236, a novel chimeric antigen receptor therapy, for solid tumors.

MNV-201 is Minovia’s second generation mitochondrial cell therapy product composed of autologous hematopoietic stem cells enriched with ...

ALX2004 is a potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors that was created ...

Mumbai: Sun Pharma Advanced Research Company Ltd. has announced submission of an Investigational New Drug (IND) application ...

has cleared its second Investigational New Drug (IND) application for MNV-201, an autologous hematopoietic stem cell product augmented with allogeneic mitochondria. The IND supports the initiation ...